 "Biocon gains over 7% after receiving EIR from USFDA")
Biocon surged 7% to Rs 420 on the BSE in early morning trade after the company said its facility received Establishment Inspection Report (EIR) with VAI (voluntary action indicated) status and closed the inspection.
The stock is trading close to its 52-week high of Rs 424 touched on July 19, 2017 in intra-day trade.
“The company confirms that the US Food and Drug Administration (FDA) has issued an EIR in relation to the cGMP (current Good Manufacturing Practice) inspection of its aseptic drug product facility that was audited between 25th May – 3rd June 2017,” Biocon said in a regulatory filing.
The FDA classified the outcome of this inspection as VAI and the EIR states that the inspection is closed, it added.
At 09:47 AM; the stock was trading 5% higher at Rs 413 as compared to 0.07% rise in the S&P BSE Sensex. A combined 2.3 million shares changed hands on the counter on the BSE and NSE so far.
The stock is trading close to its 52-week high of Rs 424 touched on July 19, 2017 in intra-day trade.
“The company confirms that the US Food and Drug Administration (FDA) has issued an EIR in relation to the cGMP (current Good Manufacturing Practice) inspection of its aseptic drug product facility that was audited between 25th May – 3rd June 2017,” Biocon said in a regulatory filing.
The FDA classified the outcome of this inspection as VAI and the EIR states that the inspection is closed, it added.
At 09:47 AM; the stock was trading 5% higher at Rs 413 as compared to 0.07% rise in the S&P BSE Sensex. A combined 2.3 million shares changed hands on the counter on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%